XT
VTGN icon

XTX Topco’s VistaGen Therapeutics VTGN Stock Holding History

XTX Topco’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Sell
118,380
-34,469
-23% -$20.8K ﹤0.01% 3851
2026
Q1 		$87.4K Buy
+152,849
New +$92.9K ﹤0.01% 3146
2025
Q4 		– Sell
-69,712
Closed -$247K – 3861
2025
Q3 		$247K Buy
+69,712
New +$208K 0.01% 1665
2022
Q3 		– Sell
-2,294
Closed -$61K – 1412
2022
Q2 		$61K Sell
2,294
-758
-25% -$26.8K 0.02% 727
2022
Q1 		$114K Buy
+3,052
New +$133K 0.05% 496

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

XTX Topco's VTGN Position: Q2 2026 in Review

XTX Topco reduced its VistaGen Therapeutics (VTGN) stake by 23% in Q2 2026, selling an estimated $20.8K and leaving 118,380 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3851.

XTX Topco first reported a position in VTGN in Q1 2022 and has held it in 5 quarters since. The position peaked at $247K in Q3 2025. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • XTX Topco held 118,380 shares of VistaGen Therapeutics worth $26.8K as of Q2 2026.
  • XTX Topco sold 34,469 VistaGen Therapeutics shares in Q2 2026, an estimated $20.8K.
  • VistaGen Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3851 holding.
  • XTX Topco first reported a position in VistaGen Therapeutics in Q1 2022 and has held it in 5 quarters since.
  • XTX Topco's VistaGen Therapeutics position peaked at $247K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.